Showing results (81-90 of 134) with videos related to

Sort By:
Pageof 14
Haematologica|July 18, 2009
Reactivation of DNA viruses in association with histone deacetylase inhibitor therapy: a case series reportDavid Ritchie, Richard L Piekarz, Piers Blombery, et al.
Cancer|November 1, 1993
Erythropoietin production. A potential marker for interleukin-2/interferon-responsive tumorsJ E Janik, M Sznol, W J Urba, et al.
Retrovirology|October 22, 2008
Anti-HTLV antibody profiling reveals an antibody signature for HTLV-I-associated myelopathy/tropical spastic paraparesis (HAM/TSP)Peter D Burbelo, Elise Meoli, Hannah P Leahy, et al.
The Journal of Clinical Endocrinology and Metabolism|September 1, 1997
Interleukin 1 alpha increases serum leptin concentrations in humansJ E Janik, B D Curti, R V Considine, et al.
Blood|February 19, 2005
B-cell recovery following rituximab-based therapy is associated with perturbations in stromal derived factor-1 and granulocyte homeostasisKieron Dunleavy, Frances Hakim, Hyun Kyung Kim, et al.
Cancer Investigation|July 29, 1998
A phase II study of carboplatin, cisplatin, interferon-alpha, and tamoxifen for patients with metastatic melanomaB L Gause, W H Sharfman, J E Janik, et al.
Cancer Immunology Research|January 7, 2018
Antigen-Specific Antitumor Responses Induced by OX40 Agonist Are Enhanced by the IDO Inhibitor IndoximodZuzana Berrong, Mikayel Mkrtichyan, Shamim Ahmad, et al.
Blood|January 10, 2009
Gene expression profiling of ATL patients: compilation of disease-related genes and evidence for TCF4 involvement in BIRC5 gene expression and cell viabilityCynthia A Pise-Masison, Michael Radonovich, Kathleen Dohoney, et al.
The Online Journal of Current Clinical Trials|July 1, 1992
Intensive therapy with cisplatin, interleukin-2 and interferon-alpha-2a in patients with metastatic melanoma. A phase II StudyM Sznol, R G Steis, J W Smith, et al.
Blood|September 11, 2004
High incidence of occult leptomeningeal disease detected by flow cytometry in newly diagnosed aggressive B-cell lymphomas at risk for central nervous system involvement: the role of flow cytometry versus cytologyUpendra Hegde, Armando Filie, Richard F Little, et al.
Pageof 14